CD19 and diffuse large B-cell lymphoma: The CAR-T cell targeting the pan-B-cell marker CD19, which became the first gene-therapy product approved by US Food and Drug Administration (FDA), had achieved largely advance in patients with relapsed or refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma, with complete remission rates of up to 90%.